- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Panacea Biotec completed enrollment for its DengiAll® Phase III clinical trial with 10,335 participants. This pivotal step advances India's first indigenous single-shot dengue vaccine, expected to enter markets by 2027 after two years of efficacy monitoring.